Registration Dossier

Diss Factsheets

Toxicological information

Skin sensitisation

Currently viewing:

Administrative data

Endpoint:
skin sensitisation: in vivo (non-LLNA)
Type of information:
experimental study
Adequacy of study:
key study
Study period:
7 May - 1 Jun 1991
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Remarks:
Also in accordance with GLP principles.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1991
Report date:
1991

Materials and methods

Test guidelineopen allclose all
Qualifier:
according to guideline
Guideline:
EU Method B.6 (Skin Sensitisation)
Version / remarks:
adopted 19. Sept. 1984
Deviations:
no
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 406 (Skin Sensitisation)
GLP compliance:
yes
Type of study:
guinea pig maximisation test
Justification for non-LLNA method:
Test was done before LLNA as first-choice method for in-vivo testing was set into force.

Test material

Constituent 1
Chemical structure
Reference substance name:
4,4'-(9H-fluoren-9-ylidene)bis(2-chloroaniline)
EC Number:
407-560-9
EC Name:
4,4'-(9H-fluoren-9-ylidene)bis(2-chloroaniline)
Cas Number:
107934-68-9
Molecular formula:
C25H18Cl2N2
IUPAC Name:
4,4'-(9H-fluoren-9-ylidene)bis(2-chloroaniline)
Test material form:
solid: particulate/powder

In vivo test system

Test animals

Species:
guinea pig
Strain:
Dunkin-Hartley
Sex:
female
Details on test animals and environmental conditions:
TEST ANIMALS
- Source: D. Hall, Newchurch, Staffordshire, England
- Age at study initiation: 6 to 7 weeks of age
- Weight at study initiation: 327 - 389 g
- Housing: in groups of ten in suspended cages with wire mesh floors
- Diet: vitamin C-enriched guinea pig diet F.D.1., ad libitum; hay was given weekly
- Water: ad libitum
- Acclimation period: 6 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21
- Humidity (%): 30-70
- Air changes (per hr): approximately 15
- Photoperiod (hrs dark / hrs light): 12/12

IN-LIFE DATES: From: 7 May To 01 June 1991

Study design: in vivo (non-LLNA)

Induction
Route:
intradermal and epicutaneous
Vehicle:
other: Alembicol D
Concentration / amount:
Induction: intradermal - 2.5% w/w; epicutaneous - 70% w/w
Challenge: epicutaneous - 25 and 50% w/w
Challenge
Route:
epicutaneous, semiocclusive
Vehicle:
other: Alembicol D
Concentration / amount:
Induction: intradermal - 2.5% w/w; epicutaneous - 70% w/w
Challenge: epicutaneous - 25 and 50% w/w
No. of animals per dose:
10 (controls), 20 (in test group)
Details on study design:
RANGE FINDING TESTS: The intradermal and topical irritancy of a range of dilutions of T-4113 was investigated to identify where possible (a) irritant test concentrations suitable for induction phase of the main study and (b) non-irritant concentrations by the topical route of administration for the challenge phase. Concentration ranges tested in two animals each were: intradermal - 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 7.5, 10.0% (w/w); topical - 10, 30, 50, 70% (w/w)

MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 2 (intradermal and epicutaneous, respectively)
- Exposure period: single intradermal injection and 48 hours topical application
- Test groups:
Intradermal - 3 pairs of injections: (1) a 1:1 mixture (v/v) Freund's Complete adjuvant (FCA)/water; (2) test substance in Alembicol D; (3) test substance in a 1:1 mixture of Freund's complete adjuvant and Alembicol D
Epicutaneous - test substance in Alembicol D
- Control group:
Intradermal - 3 pairs of injections: (1) a 1:1 mixture (v/v) FCA/water; (2) Alembicol D; (3) 1:1 mixture Freund's Complete adjuvant and Alembicol D
Epicutaneous - Alembicol D
- Site: scapular region, intradermal and epicutaneous
- Frequency of applications: every 7 days
- Duration: Days 0-9
- Concentrations: intradermal 2.5% w/w, epicutaneous 70% w/w

B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 21
- Exposure period: 24 hours
- Test groups: test substance at 25 and 50% w/w in Alembicol D
- Control group: test substance at 25 and 50% w/w in Alembicol D
- Site: anterior and posterior site on the left flank
- Concentrations: 25 and 50% w/w
- Evaluation (hr after challenge): 24, 48 and 72 hours

OTHER:
Justification for choice of vehicle: Alembicol D# is a product of coconut oil. By fractionating the fatty acids of coconut oil and re-esterifying with glycerine, a Medium Chain Triglyceride (MCT) Oil is produced. Alembicol D is such an oil. It is advantageous in this type of test in that it is stable, has a low viscosity and surface tension and is easily absorbed into the skin. These properties make it ideal as a vehicle for intradermal injections and topical applications.
Positive control substance(s):
yes
Remarks:
Formalin (checked periodically)

Results and discussion

Positive control results:
Formalin is used as positive control and checked regularly to test the stability of the assay;
concentrations used: intradermal - 0.05 -0.1%; epicutaneous - 5 -10%; challenge - 1 -5%; usually 50 - 100% of the tested animals showed sensitizing reactions in all studies conducted

In vivo (non-LLNA)

Resultsopen allclose all
Reading:
1st reading
Hours after challenge:
24
Group:
negative control
Dose level:
Challenge 25 and 50%
No. with + reactions:
0
Total no. in group:
10
Clinical observations:
Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
Reading:
2nd reading
Hours after challenge:
48
Group:
negative control
Dose level:
Challenge 25 and 50%
No. with + reactions:
0
Total no. in group:
10
Clinical observations:
Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
Reading:
other: 3rd reading
Hours after challenge:
72
Group:
negative control
Dose level:
Challenge 25 and 50%
No. with + reactions:
0
Total no. in group:
10
Clinical observations:
Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
Reading:
1st reading
Hours after challenge:
24
Group:
test chemical
Dose level:
Challenge 25 and 50%
No. with + reactions:
0
Total no. in group:
20
Clinical observations:
Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
Reading:
2nd reading
Hours after challenge:
48
Group:
test chemical
Dose level:
Challenge 25 and 50%
No. with + reactions:
0
Total no. in group:
20
Clinical observations:
Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
Reading:
other: 3rd reading
Hours after challenge:
72
Group:
test chemical
Dose level:
Challenge 25 and 50%
No. with + reactions:
0
Total no. in group:
20
Clinical observations:
Skin reactions following intradermal injections Necrosis at sites receiving FCA (test and control animals). Slight irritation in test animals for 2.5% w/w test substance in Alembicol D and control animals for Alembicol D. No dermal reaction at challenge.
Reading:
1st reading
Group:
positive control
Dose level:
Challenge 5% and 1%
No. with + reactions:
10
Total no. in group:
10

Applicant's summary and conclusion

Interpretation of results:
GHS criteria not met
Conclusions:
In this adjuvant type guinea pig test method for skin sensitisation according to OECD 406 guideline and GLP principles, the substance did not produce evidence of skin sensitization in any of the twenty test animals.
Executive summary:

Assessment of the skin sensitization potential of the test substance using the guinea-pig according to OECD 406 guideline and GLP principles. No signs of ill health or toxicity were recorded. 


Induction:

Intradermal injections: Necrosis was recorded at sites receiving FCA in test and control animals. Slight irritation was seen in test animals at sites receiving the 2.5% test substance in Alembicol D and similar signs of irritation were observed in control animals receiving Alembicol D.

Topical application: Slight erythema was observed in test animals following topical application with the 70% test substance in Alembicol D and similar signs of irritation were seen in the controls.


Challenge:

There were no dermal reaction seen in any of the test or control animals.


Based on the results, the substance did not produce evidence of skin sensitization in any of the twenty test animals.

Categories Display